See more : Archies Limited (ARCHIES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Cibus, Inc. (CBUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cibus, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Tanah Laut Tbk (INDX.JK) Income Statement Analysis – Financial Results
- Vuzix Corporation (VUZI) Income Statement Analysis – Financial Results
- China Pacific Insurance (Group) Co., Ltd. (CHPXF) Income Statement Analysis – Financial Results
- Sanghi Industries Limited (SANGHIIND.NS) Income Statement Analysis – Financial Results
- Intouch Insight Ltd. (INXSF) Income Statement Analysis – Financial Results
Cibus, Inc. (CBUS)
About Cibus, Inc.
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.82M | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 395.00K | 1.53M | 28.56M | 35.13M | 9.28M | 1.08M | 551.00K | 200.00K | 751.00K |
| Gross Profit | 1.42M | -1.38M | -2.57M | -11.28M | -1.98M | -845.00K | -43.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 78.26% | -877.07% | -9.89% | -47.28% | -27.19% | -358.05% | -8.46% | 49.87% | 40.96% |
| Research & Development | 42.37M | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.91M | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 249.02M | 5.57M | 19.00K | -126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 320.31M | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 320.70M | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 527.00K | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.89M | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 4.69M | 1.53M | 2.34M | 1.87M | 1.61M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -314.59M | -15.21M | -25.43M | -41.53M | -36.52M | -25.56M | -25.43M | -11.74M | -5.48M |
| EBITDA Ratio | -17,313.43% | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,810.59% | -4,968.11% | -2,948.37% | -445.52% |
| Operating Income | -318.88M | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -17,549.97% | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | -18.76M | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -337.64M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -18,582.44% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -4.00K | -1.45M | -114.00K | 1.56M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Net Income | -267.63M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -14,729.06% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| EPS Diluted | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| Weighted Avg Shares Out | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
| Weighted Avg Shares Out (Dil) | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
Cibus Enters into a Latin America Collaboration Agreement with Interoc to deliver rice growers an innovative rice weed control system
Cibus and Interoc announced today they have agreed to a Collaboration Agreement to introduce Cibus' two herbicide tolerance traits for rice growers in Latin America
Cibus Announces $20.3 Million Registered Direct Offering
SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it has priced an underwritten offering of 2,106,723 shares of its...
European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques
SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European...
Cibus Announces New Publication: Industrial Scale Gene Editing in Brassica napus
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that its paper on Industrializing Gene Editing in Brassica napus was published...
Cibus, Inc. (CBUS) Q3 2023 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating...
Cibus: A Pioneer In Gene Editing, The Future Of Agriculture
Gene editing, a non-GMO technology, has the potential to revolutionize agriculture by increasing crop yields, making plants more resilient, and meeting the challenges of climate change. Cibus, a company specializing in gene editing, partners with agricultural giants to develop crops...
Cibus (CBUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Cibus (CBUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 REITs That Are Overleveraged
Most REITs have strong balance sheets. But there are exceptions that are heavily overleveraged. I highlight 5 REITs that are risky.
Jim Collins to Join Cibus Board of Directors
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of...
Cibus, Inc. (CBUS) Q2 2023 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating...
Source: https://incomestatements.info
Category: Stock Reports